A Rule of 40 score of 90, free cash flow converting at approximately 3x reported net income, a confirmed wide economic moat, and 79% year-over-year revenue growth make this a high-quality growth compounder with analyst-implied upside exceeding 33% and a risk/reward ratio of roughly 4.7-to-1; the key near-term risk is a steep confirmed downtrend and heavy revenue concentration in a single diagnostic platform.
Thesis pillars
- Elite Quality Compounder Profile→Stable
- Exceptional Revenue Growth Rate→Stable
- Substantial Upside Favorable Geometry→Stable
- +2 more pillars — see the Why tab for full reasoning
Caris Life Sciences, Inc. (CAI) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $15.83, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile tissue-based profiling (84.4%); Concentration risk — Supplier: sole suppliers for next-generation sequencers.
Caris Life Sciences commercializes oncology molecular profiling through tissue-based (MI Profile/MI Cancer Seek, FDA-approved) and blood-based (Caris Assure) solutions, processing ~170,300 cases in fiscal 2025. Revenue comes from clinical testing fees and biopharma research... Read more
Hold if already holding. Not a fresh buy at $15.83, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile tissue-based profiling (84.4%); Concentration risk — Supplier: sole suppliers for next-generation sequencers. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 5/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Caris Life Sciences, Inc.
About Caris Life Sciences, Inc.
Caris Life Sciences processed approximately 170,300 MI Profile tissue-based cases in fiscal 2025, building on a cumulative dataset from over 1 million sequenced patient cases as of December 31, 2025. MI Profile—now including the FDA-approved MI Cancer Seek companion diagnostic, commercially launched in January 2025—accounted for 84.4% of 2025 revenue. The company, which completed its IPO in June 2025, serves over 6,000 ordering physicians across major health systems, academic cancer institutions, and community settings in the United States.
Caris generates revenue through clinical molecular profiling fees and biopharma research services. MI Profile delivers whole-exome and whole-transcriptome sequencing for cancer therapy selection; Caris Assure, broadly launched in the first quarter of 2024, adds blood-based liquid biopsy testing for therapy selection, with MRD and treatment monitoring applications under development. Pricing for clinical cases depends heavily on Medicare reimbursement for MI Cancer Seek under CPT code 0211U and commercial payer coverage, making annual reimbursement policy cycles a key revenue variable. Biopharma partners—including Moderna, AbbVie, Xencor, Merck KGaA, and Genentech—access the company's multi-modal clinico-genomic dataset for drug target discovery and clinical-trial patient enrollment. Key manufacturing inputs include next-generation sequencing systems from a limited number of suppliers, including sole suppliers in some cases, with no stated alternative if a sole supplier discontinues supply.
Show full overview
The FDA's PMA for MI Cancer Seek included two post-approval conditions—submission of data on interfering substances and formalin-fixed block stability—which the company completed in early November 2025. Separately, Caris Assure and other solutions marketed as laboratory-developed tests face LDT regulatory uncertainty; new FDA enforcement rules could require additional submissions and may delay the planned commercial launch of Caris Detect, a WGS blood-based early-detection assay. These parallel regulatory pathways subject the company to schedule risk across multiple product platforms simultaneously.
See also: Healthcare · Biotechnology
From Caris Life Sciences, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-27Recent Developments — Caris Life Sciences, Inc.
Latest news
- NEWS UBS Group AG Raises Stock Position in Caris Life Sciences, Inc. $CAI - MarketBeat — MarketBeat positive
- NEWS Caris Life Sciences Expands Investor Visibility With NYSE Texas Dual Listing - HarianBasis.co — HarianBasis.co positive
- NEWS Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blo — Yahoo Finance positive
- NEWS Is Caris Life Sciences, Inc. (CAI) Stock Positioned for Growth With AI-Driven Precision Medicine Expansion? - Insider Mo — Insider Monkey positive
- NEWS Is Caris Life Sciences, Inc. (CAI) Stock Positioned for Growth With AI-Driven Precision Medicine Expansion? - Yahoo Fina — Yahoo Finance positive
Generated 2026-07-27T14:48:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMI Profile tissue-based profiling84%10-K Item 1A: 'our tissue-based profiling solution, which accounted for 84.4% of our revenue for the year ended December 31, 2025'
- HIGHSuppliersole suppliers for next-generation sequencers10-K Item 1A: 'We rely on a limited number of third-party suppliers or, in many cases, sole suppliers, for some of our next-generation sequencers, lab materials, reagents, and supplies'
Material Events(8-K, last 90d)
- 2026-04-02Item 1.01LOWCaris Life Sciences entered into a Financing Agreement on April 1, 2026 with lenders managed by Blue Owl Capital and Blackstone, providing a $400 million initial term loan, $300 million delayed draw facility, and $500 million uncommitted incremental facility, secured by company assets.SEC filing →
- 2026-04-02Item 1.02MEDIUMTermination of a prior material credit agreement on April 1, 2026, coinciding with Caris Life Sciences entering the New Credit Agreement with Blue Owl Capital and Blackstone. Specific prior agreement not identified in truncated body; no disagreement cited.SEC filing →
- 2026-04-02Item 2.03LOWCaris Life Sciences created a $400 million direct financial obligation on April 1, 2026 under the New Credit Agreement with Blue Owl Capital and Blackstone. Obligation is senior secured and guaranteed by subsidiaries; no default or acceleration trigger.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $15.83, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile tissue-based profiling (84.4%); Concentration risk — Supplier: sole suppliers for next-generation sequencers. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Maintain position. Not compelling to add more. Target $23.49 (+48.4%), stop $14.70 (−7.7%), A.R:R 4.2:1. Score 6.3/10, moderate confidence.
Take-profit target: $23.49 (+48.6% upside). Target $23.49 (+48.4%), stop $14.70 (−7.7%), A.R:R 4.2:1. Stop-loss: $14.70.
Concentration risk — Product: MI Profile tissue-based profiling (84.4%); Concentration risk — Supplier: sole suppliers for next-generation sequencers; Earnings estimates trending DOWN.
Caris Life Sciences, Inc. trades at a P/E of N/A (forward 43.6). TrendMatrix value score: 5.7/10. Verdict: Hold.
16 analysts cover CAI with a consensus score of 4.2/5. Average price target: $27.
What does Caris Life Sciences, Inc. do?Caris Life Sciences commercializes oncology molecular profiling through tissue-based (MI Profile/MI Cancer Seek,...
Caris Life Sciences commercializes oncology molecular profiling through tissue-based (MI Profile/MI Cancer Seek, FDA-approved) and blood-based (Caris Assure) solutions, processing ~170,300 cases in fiscal 2025. Revenue comes from clinical testing fees and biopharma research services, with MI Profile representing 84.4% of 2025 revenue. The company completed its IPO in June 2025 with an accumulated deficit of $2.5 billion.